Pyxis Oncology has concluded its first multi-target sublicensing agreement under the new arrangement with a stealth ADC company. This expansion builds on the former agreement, which provided Pyxis ...
Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. A shipping vessel left China for Brazil while sporting some new ...
The first reviews of the Blackmagic PYXIS 6K are starting to circulate, with Sean Viljoen’s video of filming with it at the Imire Game Reserve in Zimbabwe showcasing some impressive capabilities. Sean ...
Pyxis Oncology PYXS announced that it has dosed the first patient in a phase I study of PYX-106, a fully human immunotherapy antibody candidate. The company's shares rose 4.15% on the pipeline ...
DES MOINES, IA – Briggs, a healthcare provider based in Des Moines, Iowa, has implemented a new electronic mobile data collection system that is designed to enable healthcare agencies to improve the ...
Pyxis Oncology had cash and cash equivalents, including restricted cash and short-term investments of $157.2 million. Pyxis says that its current cash, cash equivalents, and short-term investments ...
Antibody drug conjugates, or ADCs, are picking up momentum. Of the 11 drugs in this class that have been approved by the FDA, six have reached the market in the last two years. Meanwhile, new ADC ...
It’s been a good week for investors of Pyxis Oncology (NASDAQ:PYXS), to say the least. Over the past 4 sessions Pyxis shares have gained 170%, bringing the year-to-date haul to a mighty 340%. This ...
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology (“Pyxis” or the "Company”) today announced that it has entered into a worldwide license agreement with Pfizer Inc. (NYSE:PFE) for ...
Pyxis Oncology (NASDAQ:PYXS) is down ~38% in after-hours trading Wednesday after posting preliminary phase 1 data on PYX-201, an antibody-drug conjugate for solid tumors. The data presented was in six ...
BOSTON--(BUSINESS WIRE)--Pyxis Oncology, an immuno-oncology company focused on developing a new family of antibody-based immunotherapies derived from novel insights into the biology of the tumor ...
Company reports mixed Q1 results with profitability boosted by a large one-time gain from the recent sale of the product tanker "Pyxis Malou". On the flip side, average time charter equivalent ("TCE") ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback